Search Results for "product labeling" | Oncology Voice Network

Emmanuelle Jacqueta, Ghania Kerouani-Lafayeb, Francoise Grudeb, Sergio Goncalvesb, Annie Lorenced, Florence Turcryb, Liora Brunelb, Laetitia Belgodereb, Adrien Monardc, Gaëlle Guyaderb, Lotfi Boudalib, Nicolas Albin

Comparative study on anticancer drug access times between FDA, EMA and the French temporary authorisation for use program over 13 years

Apr 7^th • 12 mins read

Kushal T. Kadakia, MSc, Malke Asaad, MD, Erica Adlakha, MS, Michael J. Overman, MD, Cristina M. Checka, MD, and Anaeze C. Offodile II, MD, MPH

Virtual Clinical Trials in Oncology-Overview, Challenges, Policy Considerations, and Future Directions

Apr 8^th • 4 mins read

Thakur, Sayanta & Lahiry, Sandeep

Accelerated drug approvals in oncology: Pros and cons

Sep 14^th • 4 mins read

Sonoko Kawakatsu, René Bruno, Matts Kågedal, Chunze Li, Sandhya Girish, Amita Joshi, Benjamin Wu

Confounding factors in exposure–response analyses and mitigation strategies for monoclonal antibodies in oncology

Nov 20^th • 12 mins read

Jorge J. García, Luis E. Raez, Daniel Rosas

A narrative review of biosimilars: a continued journey from the scientific evidence to practice implementation

Aug 3^rd • 10 mins read

Shani Paluch-Shimon, Nathan I. Cherny, Elisabeth G.E. de Vries, Urania Dafni, Martine J. Piccart, Nicola Jane Latino, Fatima Cardoso

Application of the ESMO-Magnitude of Clinical Benefit Scale (V.1.1) to the field of early breast cancer therapies

Sep 6^th • 20 mins read

Peter N Morcos, Junyi Li, Iraj Hosseini, Chi‐Chung Li

Quantitative Clinical Pharmacology of T‐Cell Engaging Bispecifics: Current Perspectives and Opportunities

Nov 18^th • 15 mins read

Stefanie Broes, Robbe Saesen, Denis Lacombe, Isabelle Huys

Past, Current, and Future Cancer Clinical Research Collaborations: The Case of the European Organisation for Research and Treatment of Cancer

Aug 16^th • 8 mins read

Cornelius F Waller & Adriano Friganovi´c

Biosimilars in oncology: key role of nurses in patient education

Jun 15^th • 10 mins read

Eric Q. Konnick

The regulatory landscape of precision oncology laboratory medicine in the United States - Perspective on the past 5 years and considerations for future regulation

May 22^nd • 8 mins read

Benjamin Gregory Carlisle, Adélaïde Doussau, Jonathan Kimmelman

Patient burden and clinical advances associated with post approval monotherapy cancer drug trials: a retrospective cohort study

Feb 17^th • 7 mins read

Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Dec 20^th • 15 mins read

Idine Mousavi, BA; Timothée Olivier, MD; Vinay Prasad, MD, MPH

Cost per Event Averted in Cancer Trials in the Adjuvant Setting From 2018 to 2022

Jun 10^th • 30 mins read

Roman Adam, Ariadna Tibau, Consolación Molto Valiente, Boštjan Šeruga, Alberto Ocaña, Eitan Amir, Arnoud J. Templeton

Clinical benefit of cancer drugs approved in Switzerland 2010–2019

Jun 10^th • 35 mins read

Robbe Saesen, Georgios Kantidakis, Ann Marinus, Denis Lacombe, Isabelle Huys

How do cancer clinicians perceive real-world data and the evidence derived therefrom? Findings from an international survey of the European Organisation for Research and Treatment of Cancer

Aug 1^st • 45 mins read

John Hair, Thomas Maryon, and Cristian Lieneck

Identification of Barriers Preventing Biosimiliar Oncology Medication Adoption

Oct 27^th • 30 mins read

Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma, Sejal Porwal, Swati Gauniyal, Sukriti Vishwas, Sanjay Goyal, Gaurav Gupta, Rajaraman D. Eri, Kylie A. Williams, Kamal Dua, Sachin Kumar Singh

Biosimilars in Oncology: Latest Trends and Regulatory Status

Dec 5^th • 20 mins read

Envision Pharma Group

Patient involvement: A must-have in medicine development, but is it being overlooked in a cost-constrained environment?

May 9^th • 5 mins read